Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pet Farm

Explore full profile

Animal pharmaceutical distribution and manufacturing company

South KoreaFounded 2019Biotech & Life Sciences
Valuation $25–50M Last recorded · 2025
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Pet Farm and the history behind them.

About Pet Farm

Pet Farm, founded in December 2019 by CEO Yoon Sung-han, operates as a key player in South Korea's burgeoning pet-related economy. Yoon Sung-han, along with his son Yoon Su-ho, identified a market inefficiency where pet medications were predominantly sold at high prices through veterinary clinics, while pharmacies remained an underutilized channel. Leveraging his diverse background—which includes experience as a researcher, web programmer, and finance director—Yoon Sung-han launched the company to make animal pharmaceuticals more accessible and affordable.

The company's core business is a B2B e-commerce platform launched in May 2020, which supplies animal medicine, health supplements, and other pet products to a network of registered pharmacies. This model addresses the regulatory landscape in South Korea, where online sales of animal medicine to consumers are prohibited, by empowering physical pharmacies to become convenient access points for pet owners. Pet Farm supports its pharmacy partners by assisting with the process of registering as an animal pharmacy, managing inventory, handling returns, and providing ongoing support through regional managers. Revenue is generated from the sale and distribution of these products to its network, which has grown to approximately 6,000 member pharmacies by early 2025.

In addition to its B2B operations, Pet Farm has developed a B2C mobile application for pet owners. This app features a map to locate nearby partner pharmacies, provides information on over 300 veterinary drugs, and includes functionalities like medication reminders and diagnosis management through at-home urine test kits available at their pharmacies. The company has also established exclusive supply agreements with pharmaceutical companies such as Kwangdong Pharmaceutical and Kyongbo Pharmaceutical. A significant milestone was achieved in February 2025 when Pet Farm obtained a license to manufacture its own veterinary medicines, signaling its intent to nationalize production in a market dominated by multinational corporations and to launch its own branded products.

Source: Dealroom company data

At a glance

Founded
2019
Headquarters
South Korea
Sector
Biotech & Life Sciences

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • New Paradigm Investment

Series A8 investors entered at this stage

  • Korea Credit Guarantee Fund
  • Korea Investment Partners
  • Laguna Investment
  • Crit Ventures
  • D.CAMP
  • Eugene Asset Management
  • Stick Ventures
  • TimeWorks Investment
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇰🇷 South Korea HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pet Farm on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pet Farm on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.